Supernus Pharmaceuticals (Supernus Pharmaceuticals) Change In Inventory : $6.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals Change In Inventory?

Supernus Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $5.0 Mil. It means Supernus Pharmaceuticals's inventory declined by $5.0 Mil from Sep. 2023 to Dec. 2023 .

Supernus Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $6.1 Mil. It means Supernus Pharmaceuticals's inventory declined by $6.1 Mil from Dec. 2022 to Dec. 2023 .

Supernus Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $77.4 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Supernus Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 was 374.00.

Inventory Turnover measures how fast the company turns over its inventory within a year. Supernus Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.24.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Supernus Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.49.

Supernus Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Supernus Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Change In Inventory Chart

Supernus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-0.97

-10.12

-14.58

-17.86

6.11

Supernus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-11.55	-1.85	-3.98	6.91	5.03

Supernus Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.1 Mil.

Supernus Pharmaceuticals (NAS:SUPN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Supernus Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	80.444	/	19.627	*	365 / 4
	=	374.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Supernus Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	19.627	/	80.444
	=	0.24

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Supernus Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	80.444	/	164.314
	=	0.49

Supernus Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Executives

Tami Tillotson Martin	officer: Sr. V.P., Regulatory Affairs	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii	director	1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson	director	9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Frank Mottola	officer: Sr VP, Quality, GMP Oper. & IT	9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Jack A. Khattar	director, officer: President, CEO	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt	officer: Sr. VP of IP, CSO	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Timothy C Dec	officer: Senior Vice-President & CFO	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jonathan Rubin	officer: SVP, Chief Medical Officer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Schwabe Stefan K.f.	officer: Executive Vice President R&D	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick	officer: VP, Chief Financial Officer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly	officer: Executive Vice-President & CFO	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow	director	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn	officer: Sr. VP of Sales	C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
M James Barrett	director, 10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202